SOUTH SAN FRANCISCO, Calif.–Fluidigm Corporation announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock. Copies of the Fluidigm Corporation S-1 Registration Statement can be accessed over the Internet through the SEC’s Web site at www.sec.gov. All shares of the common stock to be sold in this offering are proposed to be sold by Fluidigm Corporation. Morgan Stanley & Co. Incorporated is acting as book-running manager, with UBS Investment Bank and Leerink Swann & Company acting as co-managers. The number of shares to be offered and the price range have not yet been determined. This offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained from Morgan Stanley & Co. Incorporated’s prospectus department at 180 Varick Street, New York, NY 10014 or by email at [email protected]. A registration statement relating to these securities has been filed with the SEC, but it has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time that the registration statement becomes effective. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction. About Fluidigm Fluidigm develops, manufactures and markets proprietary Integrated Fluidic Circuit systems for life science research. Fluidigm’s Integrated Fluidic Circuits, or IFCs, integrate a diverse set of liquid handling functions on a nanoliter scale to perform measurements, or assays, with minute volumes of reagents and samples. Fluidigm has commercialized IFC systems for a wide range of life science applications, including its BioMark system for gene expression analysis, genotyping and digital PCR, and its Topaz system for protein crystallization.